Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For Quarter And Half Year Ended September 30, 2023
Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Restructuring
Strides announces sale of manufacturing facility in Singapore for a consideration of $15m Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Conversion of Securities
Intimation under Reg 30 of SEBI (LODR) Regulations, 2015 pursuant to conversion of warrants Ex-CFO of Strides Ventures, former Axis Bank executive to set up 850 cr venture debt fund
Looks to ensure that cost of funding remains highly competitive, offering an edge in the market while not compromising on returns for its investors Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Shankar Murthy H C Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call scheduled on Monday, October 30, 2023 at 16:00 hrs IST Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings call invite scheduled on October 30, 2023 at 16:00 hrs IST Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2023 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday, October 30, 2023, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2023, amongst other matters. Further, as per provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. This is for your kind information and record purposes. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Conversion of Securities
Conversion of warrants Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd